Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Phase II Study of Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer After Chemotherapy Combined With PD-1 Antibody(Rebirth)

Next Previous
Search
Trial Profile

A Prospective Phase II Study of Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer After Chemotherapy Combined With PD-1 Antibody(Rebirth)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Tislelizumab (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Therapeutic Use
  • Acronyms Rebirth

    • Most Recent Events

    • 12 Jul 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Sep 2024.
    • 27 Jan 2024 Results assessing efficacy and safety (n=25) (data cut off date: 20 Sep 2023 at a median follow up: 258 (49-415) days) presented at the 2024 Genitourinary Cancers Symposium
    • 09 May 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top